Ieq Capital LLC Buys Shares of 34,327 AMNEAL PHARMACEUTICALS, INC. $AMRX

Ieq Capital LLC bought a new stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 34,327 shares of the company’s stock, valued at approximately $288,000.

Several other hedge funds have also recently added to or reduced their stakes in AMRX. Nuveen LLC acquired a new position in AMNEAL PHARMACEUTICALS in the first quarter valued at about $19,581,000. Vanguard Group Inc. lifted its stake in AMNEAL PHARMACEUTICALS by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after buying an additional 920,758 shares during the period. Walleye Capital LLC lifted its stake in AMNEAL PHARMACEUTICALS by 1,333.7% in the first quarter. Walleye Capital LLC now owns 558,842 shares of the company’s stock valued at $4,683,000 after buying an additional 519,863 shares during the period. Bank of America Corp DE lifted its stake in AMNEAL PHARMACEUTICALS by 218.8% in the fourth quarter. Bank of America Corp DE now owns 556,881 shares of the company’s stock valued at $4,410,000 after buying an additional 382,222 shares during the period. Finally, Invesco Ltd. lifted its stake in AMNEAL PHARMACEUTICALS by 19.2% in the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company’s stock valued at $19,045,000 after buying an additional 365,467 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

AMNEAL PHARMACEUTICALS Price Performance

Shares of AMNEAL PHARMACEUTICALS stock opened at $9.62 on Friday. AMNEAL PHARMACEUTICALS, INC. has a 1 year low of $6.68 and a 1 year high of $9.79. The business has a 50-day moving average of $8.67 and a two-hundred day moving average of $8.13. The company has a market capitalization of $3.02 billion, a P/E ratio of 962.96 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, equities analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on AMRX shares. Wall Street Zen downgraded AMNEAL PHARMACEUTICALS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 13th. The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They issued a “buy” rating and a $12.00 price target for the company. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $11.60.

Insider Transactions at AMNEAL PHARMACEUTICALS

In related news, EVP Nikita Shah sold 114,492 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the transaction, the executive vice president directly owned 152,743 shares in the company, valued at approximately $1,475,497.38. This trade represents a 42.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the transaction, the executive vice president owned 152,426 shares of the company’s stock, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 in the last ninety days. Corporate insiders own 26.56% of the company’s stock.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.